Bioactivity | DOTA Zoledronate is a next-generation agent for bone targeted radionuclide therapy for diagnosing bone metastases[1]. |
Invitro | DOTA-Zoledronate is a promising agent for the development of other future-oriented radionuclide therapy concepts for personalized nuclear oncology[1]. |
Name | DOTA Zoledronate |
CAS | 1908409-18-6 |
Formula | C23H41N7O14P2 |
Molar Mass | 701.56 |
Transport | Room temperature in continental US; may vary elsewhere. |
Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
Reference | [1]. The ITM Group Announces In-Licensing of DOTA-Zoledronate Theranostic Agent. |